These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 34250420)

  • 41. Circulating Tumor DNA in Precision Oncology and Its Applications in Colorectal Cancer.
    Arisi MF; Dotan E; Fernandez SV
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457259
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Multimodal detection of molecular residual disease in high-risk locally advanced squamous cell carcinoma of the head and neck.
    Sanz-Garcia E; Zou J; Avery L; Spreafico A; Waldron J; Goldstein D; Hansen A; Cho BCJ; de Almeida J; Hope A; Hosni A; Hahn E; Perez-Ordonez B; Zhao Z; Smith C; Zheng Y; Singaravelan N; Bratman SV; Siu LL
    Cell Death Differ; 2024 Apr; 31(4):460-468. PubMed ID: 38409276
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
    Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Personalized circulating tumor DNA monitoring improves recurrence surveillance and management after curative resection of colorectal liver metastases: a prospective cohort study.
    Li Y; Xu J; Hu X; Chen Y; Liu F; Chen Y; Ma X; Dong Q; Sun L; Mo S; Zhang L; He X; Tong S; Wu H; Li W; Cai S; Zhu S; Pan Q; Peng J
    Int J Surg; 2024 May; 110(5):2776-2787. PubMed ID: 38445460
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.
    Henriksen TV; Tarazona N; Frydendahl A; Reinert T; Gimeno-Valiente F; Carbonell-Asins JA; Sharma S; Renner D; Hafez D; Roda D; Huerta M; Roselló S; Madsen AH; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Sethi H; Aleshin A; Cervantes A; Andersen CL
    Clin Cancer Res; 2022 Feb; 28(3):507-517. PubMed ID: 34625408
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Monitoring of gastrointestinal carcinoma via molecular residual disease with circulating tumor DNA using a tumor-informed assay.
    Qi Z; Li Y; Wang Z; Tan X; Zhou Y; Li Z; Zhao W; Zheng X; Yao J; Li F; Wang W; Wang Z; Pang F; Wang G; Gu W
    Cancer Med; 2023 Aug; 12(16):16687-16696. PubMed ID: 37602656
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Detection of KRAS mutations in circulating tumour DNA from plasma and urine of patients with colorectal cancer.
    Ohta R; Yamada T; Sonoda H; Matsuda A; Shinji S; Takahashi G; Iwai T; Takeda K; Ueda K; Kuriyama S; Miyasaka T; Yokoyama Y; Hara K; Yoshida H
    Eur J Surg Oncol; 2021 Dec; 47(12):3151-3156. PubMed ID: 34315643
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular residual disease detection in resected, muscle-invasive urothelial cancer with a tissue-based comprehensive genomic profiling-informed personalized monitoring assay.
    Powles T; Young A; Nimeiri H; Madison RW; Fine A; Zollinger DR; Huang Y; Xu C; Gjoerup OV; Aushev VN; Wu HT; Aleshin A; Carter C; Davarpanah N; Degaonkar V; Gupta P; Mariathasan S; Schleifman E; Assaf ZJ; Oxnard G; Hegde PS
    Front Oncol; 2023; 13():1221718. PubMed ID: 37601688
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor.
    Siravegna G; Sartore-Bianchi A; Mussolin B; Cassingena A; Amatu A; Novara L; Buscarino M; Corti G; Crisafulli G; Bartolini A; Tosi F; Erlander M; Di Nicolantonio F; Siena S; Bardelli A
    Ann Oncol; 2017 Jun; 28(6):1302-1308. PubMed ID: 28368455
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Circulating Tumor DNA-Based MRD Assessment in Patients with CLL Treated with Obinutuzumab, Acalabrutinib, and Venetoclax.
    Fürstenau M; Weiss J; Giza A; Franzen F; Robrecht S; Fink AM; Fischer K; Schneider C; Tausch E; Stilgenbauer S; Ritgen M; Schilhabel A; Brüggemann M; Eichhorst B; Hallek M; Cramer P
    Clin Cancer Res; 2022 Oct; 28(19):4203-4211. PubMed ID: 35594173
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Utility of ctDNA in predicting response to neoadjuvant chemoradiotherapy and prognosis assessment in locally advanced rectal cancer: A prospective cohort study.
    Wang Y; Yang L; Bao H; Fan X; Xia F; Wan J; Shen L; Guan Y; Bao H; Wu X; Xu Y; Shao Y; Sun Y; Tong T; Li X; Xu Y; Cai S; Zhu J; Zhang Z
    PLoS Med; 2021 Aug; 18(8):e1003741. PubMed ID: 34464382
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Finding Waldo: The Evolving Paradigm of Circulating Tumor DNA (ctDNA)-Guided Minimal Residual Disease (MRD) Assessment in Colorectal Cancer (CRC).
    Chakrabarti S; Kasi AK; Parikh AR; Mahipal A
    Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804850
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinicopathologic Characteristics of HER2-positive Metastatic Colorectal Cancer and Detection of HER2 in Plasma Circulating Tumor DNA.
    Wei Q; Zhang Y; Gao J; Li J; Li J; Li Y; Zhou J; Lu M; Gong J; Zhang X; Shen L; Sun Y; Chang L; Wang X
    Clin Colorectal Cancer; 2019 Sep; 18(3):175-182. PubMed ID: 31227437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Circulating Tumor Cells and Circulating Tumor DNA Detection in Potentially Resectable Metastatic Colorectal Cancer: A Prospective Ancillary Study to the Unicancer Prodige-14 Trial.
    Bidard FC; Kiavue N; Ychou M; Cabel L; Stern MH; Madic J; Saliou A; Rampanou A; Decraene C; Bouché O; Rivoire M; Ghiringhelli F; Francois E; Guimbaud R; Mineur L; Khemissa-Akouz F; Mazard T; Moussata D; Proudhon C; Pierga JY; Stanbury T; Thézenas S; Mariani P
    Cells; 2019 May; 8(6):. PubMed ID: 31142037
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Clinical relevance of circulating tumor DNA assessed through deep sequencing in patients with metastatic colorectal cancer.
    Osumi H; Shinozaki E; Takeda Y; Wakatsuki T; Ichimura T; Saiura A; Yamaguchi K; Takahashi S; Noda T; Zembutsu H
    Cancer Med; 2019 Jan; 8(1):408-417. PubMed ID: 30575318
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Perioperative Dynamic Changes in Circulating Tumor DNA in Patients with Lung Cancer (DYNAMIC).
    Chen K; Zhao H; Shi Y; Yang F; Wang LT; Kang G; Nie Y; Wang J
    Clin Cancer Res; 2019 Dec; 25(23):7058-7067. PubMed ID: 31439586
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling.
    Chaudhuri AA; Chabon JJ; Lovejoy AF; Newman AM; Stehr H; Azad TD; Khodadoust MS; Esfahani MS; Liu CL; Zhou L; Scherer F; Kurtz DM; Say C; Carter JN; Merriott DJ; Dudley JC; Binkley MS; Modlin L; Padda SK; Gensheimer MF; West RB; Shrager JB; Neal JW; Wakelee HA; Loo BW; Alizadeh AA; Diehn M
    Cancer Discov; 2017 Dec; 7(12):1394-1403. PubMed ID: 28899864
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
    Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
    Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Guardant360 Circulating Tumor DNA Assay Is Concordant with FoundationOne Next-Generation Sequencing in Detecting Actionable Driver Mutations in Anti-EGFR Naive Metastatic Colorectal Cancer.
    Gupta R; Othman T; Chen C; Sandhu J; Ouyang C; Fakih M
    Oncologist; 2020 Mar; 25(3):235-243. PubMed ID: 32162812
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Survival benefit of adjuvant chemotherapy based on molecular residual disease detection in resected colorectal liver metastases: subgroup analysis from CIRCULATE-Japan GALAXY.
    Kataoka K; Mori K; Nakamura Y; Watanabe J; Akazawa N; Hirata K; Yokota M; Kato K; Kotaka M; Yamazaki K; Kagawa Y; Mishima S; Ando K; Miyo M; Yukami H; Laliotis G; Sharma S; Palsuledesai CC; Rabinowitz M; Jurdi A; Liu MC; Aleshin A; Kotani D; Bando H; Taniguchi H; Takemasa I; Kato T; Yoshino T; Oki E
    Ann Oncol; 2024 Nov; 35(11):1015-1025. PubMed ID: 39293512
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.